Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 63 Breast Neoplasms 63 Carcinoma, Non-Small-Cell Lung 39 Triple Negative Breast Neoplasms 29 Ovarian Neoplasms 25 Fallopian Tube Neoplasms 22 Squamous Cell Carcinoma of Head and Neck 17 Lung Neoplasms 16 Stomach Neoplasms 11 Neoplasm Metastasis 11 Neoplasms 9 Inflammatory Breast Neoplasms 9 Breast Neoplasms, Male 9 Melanoma 7 Esophageal Neoplasms 7 Cholangiocarcinoma 7 Uterine Cervical Neoplasms 6 Esophageal Squamous Cell Carcinoma 6 Endometrial Neoplasms 6 Carcinoma, Ovarian Epithelial 6 Pancreatic Adenocarcinoma 5 Gallbladder Neoplasms 5 Adenocarcinoma Of Esophagus 5 Adenocarcinoma 5 Urinary Bladder Neoplasms 4 Recurrence 4 Carcinoma, Transitional Cell 4 Biliary Tract Neoplasms 4 Prostatic Neoplasms 3 Peritoneal Neoplasms 3

Interventions

Nivolumab 3 Cisplatin 2 Albumin-Bound Paclitaxel 2 tislelizumab 1 spartalizumab 1 Taxes 1 Standard of Care 1 Radiotherapy 1 Neoadjuvant Therapy 1 Immunotherapy 1 Gemcitabine 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Muscle-Invasive Bladder Carcinoma × Taxes × Clear all

NCT05203913 2024-10-04

CNN-BC

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 2 Recruiting

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡